The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Tumour vascular targeting
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Searching for Peptide Ligands with an Epitope Library
Scott, J. K., & Smith, G. P. (1990) · Science · doi:10.1126/science.1696028 · Cited by 2,084
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Making antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Magnetic nanoparticles in MR imaging and drug delivery
Sun, C., Lee, J. S. H., & Zhang, M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.018 · Cited by 2,594
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Interfering with pH regulation in tumours as a therapeutic strategy
Neri, D., & Supuran, C. T. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3554 · Cited by 1,547
Self-citationRussell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Gold Nanomaterials at Work in Biomedicine
Yang, X., Yang, M., Pang, B., Vara, M., & Xia, Y. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00193 · Cited by 1,162
Size and shape effects in the biodistribution of intravascularly injected particles
Decuzzi, P., Godin, B., Tanaka, T., Lee, S.-Y., Chiappini, C., Liu, X., & Ferrari, M. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.014 · Cited by 965
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Medicinal Chemistry of Combretastatin A4: Present and Future Directions
Tron, G. C., Pirali, T., Sorba, G., Pagliai, F., Busacca, S., & Genazzani, A. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512903 · Cited by 629
Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?
Decuzzi, P., Pasqualini, R., Arap, W., & Ferrari, M. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9697-x · Cited by 616
Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence
Coppé, J.-P., Kauser, K., Campisi, J., & Beauséjour, C. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603307200 · Cited by 604
Deng, C., Jiang, Y., Cheng, R., Meng, F., & Zhong, Z. (2012) · Nano Today · doi:10.1016/j.nantod.2012.08.005 · Cited by 562
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
The adhesive strength of non-spherical particles mediated by specific interactions
Decuzzi, P., & Ferrari, M. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.05.024 · Cited by 452
Nanocarriers for drug delivery applications
Chamundeeswari, M., Jeslin, J., & Verma, M. L. (2019) · Environmental Chemistry Letters · doi:10.1007/s10311-018-00841-1 · Cited by 444
Scintillating Nanoparticles as Energy Mediators for Enhanced Photodynamic Therapy
Kamkaew, A., Chen, F., Zhan, Y., Majewski, R. L., & Cai, W. (2016) · ACS Nano · doi:10.1021/acsnano.6b01401 · Cited by 355
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
van Dongen, G. A. M. S., Visser, G. W. M., Lub-de Hooge, M. N., de Vries, E. G., & Perk, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1379 · Cited by 330
Advances in tenascin-C biology
Midwood, K. S., Hussenet, T., Langlois, B., & Orend, G. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0783-6 · Cited by 326
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Gentile, F., Chiappini, C., Fine, D., Bhavane, R. C., Peluccio, M. S., Cheng, M. M.-C., Liu, X., Ferrari, M., & Decuzzi, P. (2008) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2008.03.021 · Cited by 304
Xie, Y. J., Dougan, M., Jailkhani, N., Ingram, J., Fang, T., Kummer, L., Momin, N., Pishesha, N., Rickelt, S., Hynes, R. O., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817147116 · Cited by 296
Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A., Wessels, H. J., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03880-y · Cited by 277
Molecular imaging of the tumor microenvironment
Zhou, Z., & Lu, Z.-R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.012 · Cited by 253
Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update
Morra, L., & Moch, H. (2011) · Virchows Archiv · doi:10.1007/s00428-011-1151-5 · Cited by 256
Anticancer strategies involving the vasculature
Heath, V. L., & Bicknell, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.52 · Cited by 255
Self-citationHuang, X., Bai, X., Cao, Y., Wu, J., Huang, M., Tang, D., Tao, S., Zhu, T., Liu, Y., Yang, Y., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090397 · Cited by 156
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130
“of fibronectin, respectively, which are markers of tumor angiogenesis (8-10).”
BackgroundSelf-citationMolecular heterogeneity of tumor endothelium
Aird, W. C. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0672-y · Cited by 66
Theranostic implications of nanotechnology in multiple sclerosis: a future perspective.
Singh, A. V., Khare, M., Gade, W. N., & Zamboni, P. (2012) · Autoimmune Diseases · doi:10.1155/2012/160830 · Cited by 58
“targeted to vasculature by the attachment of the arginineglycine-aspartic acid (RGD) peptide and demonstrated many marked fold improvement in drug efficacy compared with the free drug [66, 67].”
BackgroundMicrotubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells
Kulshrestha, A., Katara, G. K., Ibrahim, S. A., Patil, R., Patil, S. A., & Beaman, K. D. (2017) · Oncotarget · doi:10.18632/oncotarget.17549 · Cited by 26
Upreti, M., Jyoti, A., Johnson, S. E., Swindell, E. P., Napier, D., Sethi, P., Chan, R., Feddock, J. M., Weiss, H. L., O’Halloran, T. V., et al. (2106) · Oncotarget · doi:10.18632/oncotarget.9490 · Cited by 21
Metadata
- Authors
- Neri, D., & Bicknell, R.
- Venue
- Nature Reviews Cancer
- Published
- 2005-06
- Volume
- 5
- Issue
- 6
- Pages
- 436-446
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2023115975
- Cited by
- 600
- References
- 138
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.